On November 6th, 2024, Aditxt Acquisition Target, Appili Therapeutics Will Hold Meeting for Shareholders to Vote on Transaction
    On November 6th, 2024, Aditxt Acquisition Target, Appili Therapeutics Will Hold Meeting for Shareholders to Vote on Transaction
    PRISM Biotech

    October 10, 2024 - by Ashlee Vogenthaler

    On November 6th, 2024, Aditxt Acquisition Target, Appili Therapeutics Will Hold Meeting for Shareholders to Vote on Transaction

    10 October 2024

    New York, October 10, 2024 - PRISM MarketView - The innovative platform company Aditxt (ADTX) who is dedicated to accelerating promising health innovations has announced one of its acquisition targets, Appili Therapeutics (APLI) has begun disseminating company information as it related to their upcoming special meeting of shareholders which will be virtually held on November 6th, 2024. Applil’s board of directors recommend shareholders to vote in favor of the proposed acquisition by Aditxt.
    Aditxt, Inc. - Prism MarketView

    Aditxt, Inc. - Prism MarketView

    Aditxt is a social innovation platform. Every year, billions of individuals face health challenges such as autoimmune diseases, misdiagnosis, infectious diseases, organ failure, reproductive health issues, malnutrition, cancer, as well as barriers to accessing healthcare. Innovations with immense potential to address critical healthcare challenges are all around us. Untapped innovations hold the key to transformative

    Read More

    Since 2015, Appili has raised CAD $100M with a focus on therapies for global infectious disease and biodefense markets. Additionally, Appili has a commercial stage pipeline. LIKMEZ™, is the first and only FDA-approved, taste-masked oral liquid suspension form of the antibiotic, metronidazole. LIKMEZ addresses an unmet need in patients, such as children and the elderly, who have trouble swallowing large pills.
    Additionally, Appili has two programs, ATI-1701 and 1801 potentially eligible for FDA Priority Review Vouchers (PRV), which upon approval would expedite the review process for future drug applications upon issuance. Notably , PRVs range from $60M to $300M, and are currently valued at around $100M.
    ATI-1701 is a live attenuated vaccine that targets tularemia which is potentially 1,000 times more infectious than anthrax, posing significant threats to public health and national security. The U.S. Air Force Academy has awarded $14M in funding to support key activities for ATI-1701, including manufacturing, non-clinical studies, and regulatory preparation for an Investigational New Drug (IND) application. Appili’s ATI-1801program is in advanced clinical trials as a novel topical treatment for cutaneous leishmaniasis (CL), a debilitating  disease that causes disfiguring skin lesions and affects hundreds of thousands of people annually, primarily in tropical and subtropical regions.  The World Health Organization has classified CL as a Neglected Tropical Disease, underscoring the ongoing need for effective treatment options.

    “Completing the acquisition of Appili would be another vehicle to expand Aditxt’s reach in addressing infectious diseases with commercial or clinical development programs. The strategic importance of Appili’s work in developing treatments and vaccines for infectious diseases and medical countermeasures could impact millions of people around the globe. We believe Appili’s team and asset portfolio could address some of the most urgent public health challenges, including antibiotic-resistant infections and bioterrorism threats.”

    Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt

    About PRISM MarketView:
    Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
    To see this content properly accept cookies.
    Disclaimer:
    PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    To see this content properly accept cookies.
    Prism MarketView | Stock Market News & Investment Opportunities
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.